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Abstract
A monoclonal antibody against the rat colon carcinoma CC531 was covalently coupled to liposomes containing a
dipalmitoylated derivative of the anticancer drug FUdR as a prodrug in their bilayers. We investigated the in vitro
interaction of these liposomes with CC531 target cells and the mechanism by which they deliver the active drug FUdR
intracellularly to the cells by monitoring the fate of the liposomal bilayer markers cholesterol-[14C]oleate and
[3H]cholesteryloleylether as well as the 3H-labeled prodrug and colloidal gold as an encapsulated liposome marker. After
binding of the immunoliposomes to the cell surface, only limited amounts were internalized as demonstrated by a low level of
hydrolysis of liposomal cholesterol ester and by morphological studies employing colloidal gold-labeled immunoliposomes.
By contrast, already within 24 h immunoliposome-incorporated FUdR-dP was hydrolyzed virtually completely to the parent
drug FUdR intracellularly. This process was inhibited by a variety of endocytosis inhibitors, indicating that the prodrug
enters and is processed by the cells by a mechanism involving an endocytic process, resulting in intracellular FUdR
concentrations up to 3000-fold higher than those in the medium. Immunoliposomes containing poly(ethyleneglycol) (PEG)
chains on their surface, with the antibody coupled either directly to the bilayer or at the distal end of the PEG chains were
able to deliver the prodrug into the tumor cells at the same rate as immunoliposomes without PEG. Based on these
observations, we tentatively conclude that during the interaction of the immunoliposomes with the tumor cells the lipophilic
prodrug FUdR-dP is selectively transferred to the cell surface and subsequently internalized by constitutive endocytic or
pinocytic invaginations of the plasma membrane, thus ultimately delivering the prodrug to a lysosomal compartment where
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hydrolysis and release of parent drug takes place. This concept allows for an efficient delivery of a liposome-associated drug
without the need for the liposome as such to be internalized by the cells. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Liposomes have been extensively studied as deliv-
ery systems for cytostatic and cytotoxic drugs [1,2].
Hydrophilic drugs can be encapsulated in the inner
aqueous phase and hydrophobic drugs can be incor-
porated into the bilayer of liposomes. The associa-
tion of a drug with liposomes usually results in a
drastic change in pharmacokinetics of the drug, in-
cluding increased circulation half-life and marked
changes in biodistribution, often resulting in reduced
toxicities and/or improved therapeutic activities [1,3].
By modifying the liposome surface with poly(ethyle-
neglycol) (PEG), further improvement in drug circu-
lation time can be achieved [4,5]. The extended cir-
culation time of such liposomes has been shown to
result in higher uptake into solid tumors by so-called
passive targeting [5,6]. In order to achieve more spe-
ci¢c tumor targeting, PEG liposomes have been de-
veloped with tumor cell-speci¢c antibodies coupled
to the lipid bilayer [7] or to the distal end of the
PEG chains [7^9]. Two important barriers limiting
successful drug targeting to tumors with liposomes
still have to be overcome: (1) limited accessibility
of target cells in solid tumors [10] and (2) a generally
limited phagocytic capacity of tumor cells, prevent-
ing e⁄cient delivery of the liposome-associated drug
to its site of action, which for most anticancer drugs
is intracellular. Although there are reports in litera-
ture describing internalization of immunoliposomes
by tumor target cells [8,11], quantities are mostly
low, while others report no uptake at all [9,12].
Even if any endocytic uptake of drug-containing lip-
osomes occurs, the drug also needs to escape in an
active form the endocytic/lysosomal compartment.
In a previous study we showed the e⁄cacy of im-
munoliposomes containing a lipophilic prodrug of
5-£uorodeoxyuridine, FUdR-dipalmitate (FUdR-
dP), towards rat CC531 colon cancer cells [13] The
monoclonal antibody CC52 (murine IgG1) that is
coupled to the liposomes, recognizes a surface anti-
gen on CC531 colon adenocarcinoma cells [14].
These immunoliposomes were ten times more e⁄-
cient in delivering FUdR-dP to tumor cells than lip-
osomes without antibody, despite a lack of uptake of
the immunoliposomes themselves. In line with an
earlier report, in which we postulated the transfer
of the lipophilic prodrug FUdR-dP from liposomal
bilayers to cell membranes [15], we proposed a sim-
ilar mechanism for the transfer of FUdR-dP from
immunoliposomes to target rat colon cancer cells.
In this study we investigated in detail the mecha-
nism by which FUdR, associated by means of a lipid
anchor with the bilayer of colon cancer cell-speci¢c
immunoliposomes, enters tumor target cells. For that
purpose we followed the fate of the immunolipo-
somes labeled with the degradable cholesteryl-
[14C]oleate ester ([14C]COA) and/or the non-degrad-
able [3H]cholesteryloleylether ([3H]COE) in their bi-
layers and colloidal gold as an encapsulated marker.
The fate of the liposomal prodrug was monitored
with [6-3H]uracil-labeled FUdR-dP. With the in
vivo application of these liposomes in mind, we in-
cluded in our studies the e¡ect of attachment of PEG
chains to the surface of the immunoliposomes as a
means to increase circulation time. The antibody was
coupled either directly to the liposomal surface by
means of MPB-PE [16] or attached to the distal
end of the PEG chains via hydrazide-PEG-DSPE
[7,17].
2. Materials and methods
2.1. Materials
5-Fluoro-2P-deoxyuridine (FUdR), N-succinimid-
yl-S-acetylthioacetate (SATA) sodium periodate, N-
acetylmethionine and cholesterol (Chol) were ob-
tained from Sigma (St. Louis, MO, USA). Egg
yolk phosphatidylcholine (eggPC), maleimido-4-(p-
phenylbutyryl)phosphatidylethanolamine (MPB-PE)
and methoxy-poly(ethyleneglycol)2000-distearoylphos-
phatidylethanolamine (mPEG-DSPE) were pur-
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chased from Avanti Polar Lipids (Birmingham, AL,
USA). Hydrazide-PEG-DSPE (Hz-PEG-DSPE) was
synthesized as described previously [18]. Cholesteryl-
[14C]oleate and [3H]cholesteryloleylether were ob-
tained from Amersham (Buckinghamshire, UK),
5-[6-3H]£uoro-2P-deoxyuridine ([3H]FUdR) was ob-
tained from DuPont NEN (Wilmington, USA). Se-
phadex G-50 and Sepharose CL-4B were from Phar-
macia (Uppsala, Sweden). All other chemicals were
analytical grade or the best grade available.
2.2. Monoclonal antibody
The monoclonal antibody CC52 (IgG1), recogniz-
ing a surface antigen on CC531 colon adenocarcino-
ma cells was developed in the department of Pathol-
ogy, Leiden University Medical Center, the
Netherlands [14] and was puri¢ed from culture
supernatant by protein A-Sepharose (Pharmacia,
Woerden, The Netherlands) chromatography, ac-
cording to the manufacturers instructions.
2.3. Synthesis of radioactive 3P,5P-O-dipalmitoyl-
FUdR (FUdR-dP)
Radioactively labeled FUdR-dP was synthesized
as described earlier [19]. Brie£y, 100 WCi of
[3H]FUdR was added to 4 Wmol of FUdR dissolved
in methanol. This mixture was dried under reduced
nitrogen pressure, and subsequently 8 Wmol of pal-
mitoylchloride dissolved in dimethylacetamide was
added. The mixture was incubated overnight under
constant shaking at 40‡C. Water was added to the
mixture and the prodrug was extracted with chloro-
form/methanol (4:1). The purity of the FUdR-dP
was checked by thin-layer chromatography on silica
gel F254 plates (Merck, Darmstadt, Germany) with
chloroform/methanol (95:5) as an eluent. The specif-
ic activity of the product was 25 WCi/Wmol.
2.4. Liposome preparation
MPB liposomes were composed of eggPC, Chol
and MPB-PE (23:16:1 molar ratio). MPB-PEG lip-
osomes were composed of eggPC, Chol, MPB-PE
and mPEG-DSPE (23:16:1:1.6 molar ratio). Hz-
PEG liposomes were composed of eggPC, Chol,
Hz-PEG-DSPE and mPEG-DSPE (23:16:1:0.6 mo-
lar ratio). 0.02 Wmol [3H]FUdR-dP was incorporated
in the liposomes per Wmol of lipid. When required,
liposomes were labeled with trace amounts of
[3H]cholesteryloleylether ([3H]COE) (1 WCi/Wmol lip-
id) and/or cholesteryl-[14C]oleate ([14C]COA) (0.4
WCi/Wmol lipid). Lipids dissolved in chloroform/
methanol (9:1, v/v) were mixed and dried under ni-
trogen, dissolved in cyclohexane and lyophilized. The
lipids were then either hydrated in HN-bu¡er (10
mM Hepes, 135 mM NaCl), pH 7.4 or, for coupling
of antibodies to MPB-PE-containing liposomes, in
HN-bu¡er, pH 6.7 or, for coupling of antibodies to
Hz-PEG-DSPE-containing liposomes, in NaAc-bu¡-
er, pH 5.5 (100 mM sodium acetate, 70 mM NaCl).
Gold containing liposomes were prepared by hydra-
tion of the dried lipid with cold gold chloride/citrate
solution consisting of 3.18 mM HAuCl4, 2.5 mM
K2CO3, 10.2 mM trisodium citrate (pH 6.0^6.2) as
described before [20]. Liposomes were sized by re-
peated extrusion through polycarbonate ¢lters with
a pore size of 50 nm (Costar Cambridge, MA, USA).
using a high pressure extruder (Lipex Biomembranes,
Vancouver, Canada). In the case of preparation of
gold-containing liposomes, gold sols were formed by
incubating the liposome suspension at 37‡C for 30
min. Phospholipid phosphorus of each liposome
preparation was determined by a phosphate assay
after perchloric acid destruction [21]. Total liposomal
lipid concentrations were calculated, taking into ac-
count the amount of cholesterol in the liposome
preparations. Particle size and size distribution were
determined by dynamic laser light scattering with a
Nicomp model 370 submicron particle analyzer
(Nicomp, Santa Barbara, CA, USA). The diameter
of the liposomes was obtained from the volume dis-
tribution curves produced by the particle analyzer.
Liposomes had an average diameter of 80 nm.
2.5. Coupling of antibodies to liposomes
The monoclonal antibody CC52 was coupled to
MPB-PE-containing liposomes by a sulfhydryl^mal-
eimide coupling method as described previously [16].
Brie£y, free sulfhydryl groups were introduced in the
CC52, using the heterobifunctional reagent SATA
(N-succinimidyl-S-acetylthioacetate). Free SATA
was separated from the derivatized CC52 by gel per-
meation chromatography using Sephadex G-50. Re-
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active sulfhydryl groups were induced by deacetylat-
ing the acetylthioacetate-CC52 for 30 min by addi-
tion of 100 Wl freshly prepared solution of 0.5 M
Hepes, 0.5 M hydroxylamine^HCl, 0.025 M EDTA
(pH 7.0) per ml of antibody solution. Deacetylated
antibody and MPB-containing liposomes were incu-
bated for 4 h at room temperature at a ratio of 0.3
mg antibody per Wmol of liposomal lipid. 50 Wl N-
Ethylmaleimide (8 mM in HN-bu¡er, pH 7.4) was
added per 300 Wl antibody^liposome solution to cap
unreacted sulfhydryl groups. Unconjugated antibody
was separated from liposomes by £otation on a met-
rizamide gradient as described before [22]. Hereafter,
CC52 liposomes were extensively dialyzed against
HN-bu¡er, pH 7.4.
The monoclonal antibody CC52 was coupled to
Hz-PEG-DSPE-containing liposomes via a hydra-
zone-linkage of the hydrazide moiety at the distal
end of the PEG chains and oxidized carbohydrates
in the Fc-region of the antibody as described previ-
ously [7,9,17]. Brie£y, CC52 antibody was oxidized
using 100 Wl sodium periodate (10 mM) per ml of
antibody solution for 1 h at room temperature. Un-
reacted periodate was quenched by adding 100 Wl N-
acetylmethionine (0.5 M) per ml of antibody solu-
tion. Oxidized antibody was incubated with Hz-
PEG-DSPE-containing liposomes in a ratio of 0.3
mg antibody per Wmol of total lipid, overnight at
4‡C. Uncoupled antibody was separated from immu-
noliposomes by gel permeation chromatography us-
ing Sepharose CL-4B with HN-bu¡er (pH 7.4) as an
eluent.
Immunoliposomes were characterized by determin-
ing protein content [23], phospholipid phosphorus
content and particle size. The amounts of antibody
coupled to liposomes were 70^160 Wg/Wmol lipid for
CC52-MPB liposomes, 30^40 Wg/Wmol lipid for
CC52-MPB-PEG, and 13 Wg/Wmol lipid for CC52-
Hz-PEG liposomes, resulting in sizes of 140^180
nm, 90^120 nm and 100^140 nm, respectively. No
aggregates were observed. Liposomes were stored at
4‡C under nitrogen and used within two weeks after
preparation.
2.6. Cell culture
CC531 colon adenocarcinoma is a 1,2-dimethylhy-
drazine-induced carcinoma of the colon of WAG/
Rij-rats [24]. Cells were maintained in 75-cm2 culture
£asks (Costar, Cambridge, MA, USA) in RPMI
1640 medium with 25 mM Hepes (Gibco BRL,
Breda, The Netherlands) supplemented with 10%
heat-inactivated fetal calf serum (FCS) (Gibco),
fresh L-glutamine (2 mM) and penicillin/streptomycin
(100 U/ml and 100 Wg/ml, respectively) (Gibco) at
37‡C in a humidi¢ed atmosphere consisting of
5% CO2 in air. Cells were subcultured at 80% con-
£uence.
In all experiments cells were trypsinized (0.05%
trypsin) and 1U105 cells were plated in 6-well plates
(Costar) and left to adhere and grow for 2 days. One
hour before the start of the experiment cells were
washed with PBS (137.9 mM NaCl, 2.7 mM KCl,
8.1 mM Na2HPO4 and 1.5 mM KH2PO4, pH 7.4)
and 1.5 ml fresh medium with or without 10% FCS
was added to the cells. Unless stated otherwise, all
incubations were performed at 37‡C.
2.7. Association, cellular uptake and degradation of
liposomes
CC531 cells were incubated with [3H]COE-labeled
CC52 liposomes (100 nmol) for 4, 8, 24 and 48 h
continuously or for 3 h followed by a liposome-free
incubation period of 0, 3, 6, 24 or 48 h. Incubations
were terminated by removing the incubation medium
followed by thorough washing of the cells with ice-
cold PBS. Cells were harvested by trypsinization with
trypsin (0.05%) for 10 min at 37‡C, centrifugation
and a subsequent wash of the cell pellet with PBS.
Label removable by the trypsin treatment was deter-
mined in the combined supernatants, representing
cell-bound liposomes; non-removable label was de-
termined in the cell pellet after lysing the cells
with 10% sodium dodecyl sulfate (SDS). Total cell-
associated label was determined by combining the
radioactivity in the supernatant (removable label)
and the cell pellet (non-removable label) and was
normalized for the amount of cellular protein as
determined by protein assay [25] using BSA as a
standard.
For determining uptake and degradation, lipo-
somes were double-labeled with [3H]COE, a non-de-
gradable marker and [14C]COA, an intracellularly
degradable marker, which after degradation results
in release of [14C]oleate into the medium and a con-
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comitant increase in the 3H/14C ratio of the cell-as-
sociated radioactivity [26,27]. Cells were incubated in
the presence of 10% FCS in order to extract the
released [14C]oleate from the cells. Cells were incu-
bated and harvested as described above. The percent-
age of hydrolyzed [14C]COA and thus the percentage
of liposome degradation was calculated by normaliz-
ing the 3H/14C ratio of the cell-associated radioactiv-
ity at each time point for the initial 3H/14C ratio
using the equation:
% hydrolysis of 14CCOA3H=14C ratio at t  x=
3H=14C ratio at t  031U100 1
2.8. Uptake and metabolism of immunoliposome-
incorporated [3H]FUdR-dP by CC531 cells
CC531 cells were incubated with [3H]FUdR-dP in-
corporated in CC52-MPB liposomes, CC52-MPB-
PEG liposomes, CC52-Hz-PEG liposomes or control
liposomes without antibody (50 or 100 nmol lipid) or
with free [3H]FUdR (2 nmol) as described above.
Radioactivity was measured in the medium, in the
supernatant after trypsin treatment and centrifuga-
tion (trypsin-removable), and in the trypsin-treated
cell pellet (non-removable) after lysing the cells
with 10% SDS.
To distinguish between hydrophobic FUdR-dP
and hydrophilic FUdR or metabolites (hydrolyzed
prodrug), chloroform/methanol extractions were per-
formed on samples of all three fractions. Brie£y, 1 ml
of sample was mixed with 2.5 ml methanol and 1 ml
chloroform. Hereafter 1.25 ml of chloroform and
1.25 ml of PBS were added to this mixture and the
resulting biphasic system was centrifuged for 10 min
at 1500Ug. The chloroform and methanol/water
layers were isolated, dried under vacuum and redis-
solved in 200 Wl of chloroform/methanol (9:1, v/v) or
400 Wl PBS, respectively. 3H-Label was measured by
liquid scintillation counting. The distribution of the
3H-label in the di¡erent fractions, i.e., medium, tryp-
sin-removable, trypsin-non-removable, organic phase
and water phase, was calculated as a percentage of
the total amount of label retrieved.
The intra- and extracellular concentrations of the
active drug FUdR were calculated using the amounts
of label that were water-soluble in the chloroform/
methanol extractions of the cell fraction and the me-
dium fraction, respectively. The volume of the incu-
bation medium was 1.5 ml, the volume of the tumor
cells was calculated assuming a spherical cell shape
with an average diameter of 14 Wm and assuming
that 2 days after plating 1U105 cells the cell number
was 2U105 (adherence for 24 h, doubling time of the
cell line after adherence is approximately 1 day). Be-
cause of the absence of FCS during the incubations,
the cells did not proliferate as evidenced by a con-
stant level of cellular protein determined using the
protein assay as described above. During the trypsin
treatment for the removal of cell-bound liposomes,
water-soluble label was leaking from the intracellular
pool. The amount of water-soluble label detected in
the cells was corrected for this trypsin-induced leak-
age by adding the released amounts to the intracel-
lular amounts of water-soluble label actually meas-
ured, together representing the total fraction of
water-soluble FUdR intracellularly.
2.9. Inhibition of endocytosis and intralysosomal
degradation
CC531 cells were incubated with CC52-MPB lip-
osomes (50 nmol lipid) containing [3H]FUdR-dP for
3 h followed by a liposome-free incubation period of
0, 3 or 6 h in the absence of FCS. E¡ects of the
following inhibitors of endocytosis and intralysoso-
mal degradation on the hydrolysis of liposomal
FUdR-dP were measured: colchicine (50 mM), an
inhibitor of microtubule polymerization, cytochala-
sin B and D (20 Wg/ml), both inhibitors of actin
polymerization, the ionophore monensin (20 mM)
an inhibitor of vesicular transport, chloroquine
(50 and 100 mM) and NH4Cl (10 and 20 mM),
both lysosomotropic amines known to increase
intralysosomal pH. Inhibitors were added 5 min pri-
or to the addition of the liposomes. Except for the
control incubations, inhibitors were present during
the 3-h incubation with liposomes and during the
liposome-free incubation time. Incubations were
stopped by removing the incubation medium and
subsequent washing with PBS. Radioactivity was de-
termined in the medium and in the cells after lysis
with NaOH (0.4 M). The percentage of label in the
medium is taken as the percentage of hydrolyzed
FUdR-dP.
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2.10. Electron microscopy
CC531 cells were incubated with colloidal gold-
containing CC52-MPB liposomes for 3 or 24 h with-
out FCS. Incubations were stopped by removing the
liposome-containing medium and subsequent wash-
ing with ice-cold PBS. The cells were ¢xed in situ in
2% glutaraldehyde in 0.1 M cacodylate bu¡er (v/v)
during 2 h at 4‡C. The cells were processed for resin
histology employing post¢xation in a 1:1 mixture (v/
v) of OsO4, 2 g/100 ml in distilled water and
K3Fe(CN)6, 3 g/100 ml in 0.2 M cacodylate bu¡er,
with pH 7.4, ethanol dehydration and embedded in
Epon 812 epoxy resin. After polymerization sections
with a thickness of 70^90 nm were cut with an ultra-
microtome (LKB III Ultratome, LKB Producter,
Stockholm, Sweden). Sections were collected on cop-
per G200 grids and stained with aqueous uranyl ace-
tate and lead citrate (Reichert Ultrastainer Leica,
Rijswijk, The Netherlands) and examined at an ac-
celerating voltage of 60 kV in a Philips EM201 trans-
mission electron microscope (Philips Analytical,
Electron Optics, Eindhoven, The Netherlands).
2.11. Statistics
Statistical signi¢cance of di¡erences was evaluated
by a two-tailed unpaired Student’s t-test.
C
Fig. 1. Association of CC52-MPB liposomes with CC531 cells
with time and the distribution in trypsin-removable or non-re-
movable liposomes. (A) CC531 cells were incubated with CC52-
MPB liposomes (100 nmol), labeled with [3H]COE in the pres-
ence (b) or absence (a) of 10% FCS for the indicated periods
(n = 3). Cell-associated radioactivity was determined and nor-
malized for the amount of cellular protein. (B,C) Distribution
of cell-associated CC52-MPB liposomes in trypsin-removable
(v) or non-removable (E) fractions. Cells were incubated with
[3H]COE-labeled immunoliposomes (B) continuous for 4, 8 or
24 h (n = 3) or (C) for 3 h followed by a liposome-free incuba-
tion period of 0, 3 (n = 9), 6 or 24 h (n = 6), in the absence of
FCS. At the end of the incubation, cells were treated for 10
min with trypsin at 37‡C. Removable and non-removable frac-
tions were separated by centrifugation as described in Section
2. Radioactivity was determined in both fractions and normal-
ized for the amount of cellular protein.
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3. Results
3.1. Association of [3H]cholesterol ether-labeled
immunoliposomes with CC531 cells
Fig. 1A presents the association of [3H]COE-la-
beled immunoliposomes with CC531 cells in time in
the presence or absence of 10% FCS. There was a
steady increase in the amount of label associating
with the cells over a period of up to 24 h, irrespective
of the presence of FCS. In order to discriminate
between bound and internalized liposomes, cells
were incubated with trypsin. Fig. 1B shows that
4 to 8 h after incubation, around 20% of the label
remained cell-associated after trypsin treatment and
that this level slightly increased during 24 h. After a
3-h incubation with liposomes and a subsequent in-
cubation without liposomes there was an increase of
20% in the amount of non-removable cell-associated
liposomes and a concomitant decrease of immunoli-
posomes that could be removed by trypsin during the
¢rst 6 h (Fig. 1C). These observations may be ex-
plained by internalization of the liposomes or alter-
natively by an increase in the strength of the binding
of immunoliposomes with the tumor cells in time,
reducing the amount of liposomes removable by
the trypsin treatment. Evidence compatible with the
latter explanation is shown in Table 1. Incubation of
CC531 cells with CC52 liposomes for 3 h at 4‡C
resulted in a signi¢cantly lower amount of immuno-
liposomes binding to the tumor cells, whereas a high-
er amount of the associated label was removable by
trypsin than upon incubation at 37‡C, suggesting a
weaker interaction of immunoliposomes with tumor
cells at 4‡C resulting in turn in more e¡ective remov-
al by trypsin.
Fig. 2. Hydrolysis of immunoliposome-incorporated cholesteryl-
[14C]oleate by CC531 cells as a measure of liposome uptake
and degradation. Tumor cells were incubated continuously (A)
or for 3 h followed by a liposome-free incubation time (B) in
the presence of 10% FCS with 100 nmol of immunoliposomes
double-labeled with [3H]COE, a non-degradable marker, and
[14C]COA, an intracellularly degradable marker, which after
degradation results in a release of [14C]oleic acid into the me-
dium and a subsequent increase in the 3H/14C ratio of the cell-
associated radioactivity. From the increase in isotope ratio the
percentage of hydrolysis was calculated according to Eq. 1
from Section 2 (n = 5).
Table 1
In£uence of temperature on the interaction between [3H]COE-labeled immunoliposomes and tumor cells
Liposome Fraction 37‡C 4‡C P value
CC52-MPB-PEG Total cell-associated liposomes (nmol/mg) 3.72 þ 1.32 0.53 þ 0.19 0.0005
% Removable 84.0 þ 4.3 94.2 þ 3.4 0.004
% Non-removable 16.0 þ 4.3 5.8 þ 3.4 0.004
CC531 cells were incubated for 3 h at 4‡C or 37‡C with 100 nmol of immunoliposomes (n = 6). The amount of cell-associated CC52-
MPB-PEG liposomes was determined and normalized for the amount of cellular protein. The distribution in trypsin-removable or
non-removable fractions is presented as a percentage of total label ( þ S.D.).
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The presence of FUdR-dP in the bilayer of the
immunoliposomes had no e¡ects on the association
of immunoliposomes with CC531 cells under any of
the conditions applied (not shown).
3.2. Degradation of immunoliposomes
The degradation of CC52-PC/Chol liposomes by
CC531 colon cancer cells was measured by using
Fig. 3. Transmission electron micrographs of thin sections of cultured CC531 cells incubated with CC52-MPB-PEG liposomes contain-
ing colloidal gold as an encapsulated marker. (A) Binding of colloidal gold-containing CC52 immunoliposomes to the cell surface of a
CC531 cell after a 3-h incubation, representing a typical example of the morphology after a 3-h incubation (bar = 300 nm). (B) CC531
cell with cell surface-bound gold-containing immunoliposomes and gold grains present in an early endosome (bar = 300 nm). (C)
CC531 cell with internalized colloidal gold particles associated with liposome-like structures in an endosomal compartment of the cell
(bar = 200 nm). (D) Colloidal gold present in lysosomes (indicated by the arrows). The latter two panels represent an only occasionally
observed internalization of immunoliposomes 24 h after incubation with CC52 immunoliposomes (bar = 200 nm).
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double-labeled liposomes containing the metabol-
ically inert cholesterol ether, [3H]COE, and the me-
tabolizable cholesterol ester, [14C]COA. If the lipo-
some encounters a cellular compartment containing
hydrolytic enzymes, the cholesterol ester will be hy-
drolyzed. The 14C-labeled oleate will be released and
can leave the cell, thus causing an increase in the
cellular 3H/14C ratio. From the increase in isotope
ratio the percentage of hydrolysis of [14C]COA and
thus of the liposomes was calculated.
During a continuous incubation with immunolipo-
somes (Fig. 2A), as well as after a 3-h pre-incubation
period with immunoliposomes followed by a lipo-
some-free incubation period (Fig. 2B), only low lev-
els of hydrolysis of the [14C]COA were observed.
During a 48-h continuous incubation or during 48
h following a 3-h preincubation period, hydrolysis
of the cell-associated cholesterol ester amounted to
less than 20%, i.e., a rate of hydrolysis of less than
0.5% per hour.
3.3. Interaction of colloidal gold-containing
immunoliposomes with CC531 cells
Immunoliposomes, containing colloidal gold as an
encapsulated marker, showed substantial binding to
CC531 cells after a 3-h incubation as visualized by
transmission electron microscopy (Fig. 3A). A vast
majority of the cells were observed to have only cell
surface-bound liposomes after a 3 or 24 h incubation
with CC52-MPB liposomes. Only occasionally inter-
nalization of liposomal gold grains was observed;
after a 3-h incubation this amounted to a few single
gold particles in an early endosomal compartment
(Fig. 3B) and after a 24-h incubation, in a few cells
multiple gold particles were observed associated with
membrane structures contained within endosomal
compartments (Fig. 3C) or gold grains present in
lysosomes (Fig. 3D). The internalization of immuno-
liposomes by only a fraction of the tumor cells in
these morphological studies conceivably is re£ected
in low levels of hydrolysis of immunoliposomal cho-
lesterol ester we observed in Fig. 2.
3.4. Immunoliposome-incorporated [3H]FUdR-dP
The metabolic fate of the liposomal FUdR-dP was
studied by monitoring the 3H-label in the uracil moi-
ety of FUdR-dP.
In contrast to our observations on the cholesterol
ester, the FUdR-dP in CC52 immunoliposomes was
rapidly hydrolyzed by the tumor cells (Fig. 4). With-
in 6 h more than 50% of the FUdR-dP associating
with the tumor cells during a 3-h preincubation, was
Table 2
Fractionation of 3H-label in chloroform- and water-soluble fractions after incubation of CC531 cells with [3H]FUdR-dP-containing
immunoliposomes
Fraction Time after incubation (h) Percentage of chloroform-soluble label Percentage of water-soluble label
Medium 0 0 0
3 17.0 þ 11.6 83.0 þ 11.6
6 12.6 þ 9.2 87.4 þ 9.2
24 17.2 þ 1.8 82.8 þ 1.8
Removable 0 86.9 þ 9.1 13.1 þ 9.1
3 91.9 þ 2.0 8.1 þ 2.0
6 89.9 þ 5.8 10.1 þ 5.8
24 88.6 þ 4.4 11.4 þ 4.4
Non-removable 0 55.3 þ 8.2 44.7 þ 8.2
3 55.2 þ 18.1 44.8 þ 18.1
6 52.2 þ 4.9 47.8 þ 4.9
24 42.3 þ 3.1 57.7 þ 3.1
After incubating CC531 cells for 3 h with [3H]FUdR-dP-containing immunoliposomes followed by a liposome-free incubation time of
0, 3, 6 (n = 8) or 24 h (n = 3), medium and cell-associated (trypsin-removable or non-removable) samples were fractionated by chloro-
form/methanol extractions as described in Section 2. Data are expressed as percentage of retrieved label in either of the fractions
( þ S.D.)
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hydrolyzed as shown by the release of 3H-label in the
medium, increasing to 80% in 24 h. As hydrolysis
proceeded, the amount of trypsin-removable label
decreased from more than 80% at the start of the
incubation to less than 20% after 24 h. The non-re-
movable label decreased in the same time from 20%
to 7%.
We further analyzed the nature of the cell-associ-
ated label, both trypsin-removable and non-remov-
able, as well as the released radioactivity by fraction-
ating these into chloroform- and water-soluble
fractions so as to distinguish between the initial
chloroform-soluble prodrug and its water-soluble
metabolites (Table 2). Eighty to 90% of the label in
the medium was water-soluble, representing com-
pletely deacylated prodrug; the remaining 10% to
20% was chloroform-soluble, representing intact pro-
drug. By contrast, as much as 90% of the cell-asso-
ciated label that was trypsin-removable, was re-
trieved in the chloroform phase, representing
liposomal FUdR-dP associated with cell-surface-
bound liposomes. Only a small fraction of the tryp-
sin-removable label (around 10%) was water-soluble,
representing intracellularly formed FUdR, which was
released from the cells due to the treatment with
trypsin. Of the label that remains cell-associated after
trypsin treatment, 42% to 55% was present in the
organic phase, representing di- and/or mono-acylated
FUdR, while 45% to 58% was detected in the water
phase, representing intracellular FUdR or metabo-
lites of FUdR. The amount of chloroform-soluble
label tended to decrease in time, indicating the con-
tinuous hydrolysis of the prodrug. The presence of
FCS had no e¡ect on the results (not shown).
Within 24 h most of the immunoliposomal FUdR-
dP which was associated with the cells during a 3-h
incubation had been hydrolyzed to water-soluble
FUdR (Fig. 4 and Table 2) of which the major
part (76^82%) was detected outside the cells and a
smaller amount (18^24%) inside the cells (Table 3).
Taking into consideration the large di¡erence be-
tween the intra- and extracellular volumes (approx-
imately 5U104-fold) we can calculate that, depending
on the incubation time, the intracellular FUdR-con-
centration was as much as 700^3000-fold higher than
that in the medium (Table 3). The di¡erence between
the amounts of prodrug that were delivered to the
tumor cells by immunoliposomes and by liposomes
without antibody is presented in Table 4. With im-
Table 3
Distribution of hydrolyzed [3H]FUdR-dP from CC52-MPB-liposomes between medium and cell fractions
Time after incubation
(h)
Percentage of FUdR in
medium
Percentage of FUdR
intracellular
Ratio intracellular/extracellular
FUdR-concentration
3 76.5 þ 2.9 23.5 þ 2.9 2979.9 þ 888.3
6 81.9 þ 9.4 18.1 þ 9.4 1747.3 þ 208.8
24 95.0 þ 1.2 5.0 þ 1.2 784.2 þ 163.3
Water-soluble 3H-label in medium and cells was determined by chloroform/methanol extractions after incubating cells for 3 h with lip-
osomes followed by a liposome-free incubation time of 3, 6 (n = 6) or 24 h (n = 3). Ratio of FUdR-concentration in cells vs. medium
was calculated from the water-soluble 3H-label determined in medium and cells, assuming the presence of 2U105 cells with an average
diameter of 14 Wm.
Fig. 4. Metabolic fate of [3H]FUdR-dP incorporated in CC52-
MPB liposomes during interaction with CC531 cells. Distribu-
tion of 3H-label in medium (a), trypsin-removable (O) or non-
removable (E) fractions after a 3-h incubation of CC531 cells
with [3H]FUdR-dP-containing CC52-MPB liposomes followed
by a liposome-free incubation time, both in the absence of FCS
(n = 8).
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munoliposomes, a 30-fold higher level of [3H]FUdR-
dP was associated with CC531 cells after 3 h incuba-
tion as compared to liposomes without antibody.
This di¡erence in the delivery of the prodrug was
shown before to result in a much higher antiprolifer-
ative activity of immunoliposomal FUdR-dP than
FUdR-dP in liposomes without antibody [13].
3.5. E¡ect of inhibitors
In order to gain further insight into the mechanism
of interaction of the liposomal prodrug with the cells,
we determined the e¡ects of inhibitors of endocytosis
and intralysosomal degradation on the hydrolysis of
[3H]FUdR-dP incorporated in immunoliposomes
(Fig. 5). Except for colchicine, all inhibitors of endo-
cytosis resulted in a substantial inhibition of the hy-
drolysis of FUdR-dP (Fig. 5A). Inhibition varied
from about 65% for monensin to more than 80%
for cytochalasin D. At 4‡C there was no detectable
hydrolysis (not shown). Inhibition of intralysosomal
degradation with NH4Cl or chloroquine also resulted
in major inhibition of the hydrolysis of FUdR-dP
(Fig. 5B).
Table 4
E⁄ciency of delivery of FUdR-dP to CC531 cells by immunoliposomes vs. control liposomes without antibody
Time after incubation (h) Cell-associated FUdR(-dP) (pmol/mg cell protein)
MPB liposomes CC52-MPB liposomes
0 3.6 þ 0.9 100.4 þ 5.7
3 3.1 þ 1.1 78.6 þ 3.0
6 4.0 þ 1.3 59.1 þ 3.0
Cell-associated 3H-label was measured in time after a 3-h incubation with [3H]FUdR-dP incorporated in CC52-MPB liposomes
(n = 12) or MPB liposomes (n = 6) without antibody.
Fig. 5. E¡ect of inhibitors of endocytic uptake (A) or intralyso-
somal degradation (B) on the hydrolysis of [3H]FUdR-dP from
CC52-MPB liposomes by CC531 cells. CC531 cells were incu-
bated for 3 h with 50 nmol liposomes containing [3H]FUdR-dP
followed by a liposome-free incubation time of 3 or 6 h, both
in the absence of FCS. The percentage of label in the medium
is taken as the percentage of hydrolyzed FUdR-dP. (A) Incuba-
tions (all n = 6): control (¢lled bars), colchicine (wide cross-
hatched bars), monensin (narrow cross-hatched bars), cytocha-
lasin B (horizontally hatched bars), cytochalasin D (vertically
hatched bars). (B) Incubations (all n = 6): control (¢lled bars),
NH4Cl (10 mM) (wide cross-hatched bars), NH4Cl (20 mM)
(narrow cross-hatched bars), chloroquine (50 mM) (horizontally
hatched bars) and chloroquine (100 mM) (vertically hatched
bars).
6
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3.6. E¡ects of PEG
The e⁄ciency of delivering the drug to the tumor
cells by immunoliposomes with or without PEG or
by adding free FUdR was followed in time after a
3-h preincubation period with liposomal [3H]FUdR-
dP or free [3H]FUdR.
Fig. 6A shows that PEG, either in the case that
antibody is coupled directly to the bilayer or when
attached at the distal end of the PEG chain, has an
inhibitory e¡ect on the amount of prodrug associat-
ing with the cells. Nonetheless, the two PEG immu-
noliposomes are still far more e⁄cient in delivering
the drug than free FUdR or as compared to lipo-
somes without antibody as is shown in Table 4. The
decrease in the amount of cell-associated label in
time was caused by the ongoing hydrolysis of
FUdR-dP by the tumor cells and a subsequent re-
lease of drug in the medium (Fig. 6B), demonstrating
that the FUdR-dP delivered to the tumor cells by
PEG immunoliposomes was hydrolyzed. Fig. 6C
shows that there was virtually no di¡erence between
immunoliposomes with and without PEG in the rate
of intracellular hydrolysis of [3H]FUdR-dP by the
tumor cells, as revealed by the rates of appearance
of label in the medium. These results indicate that
there is no di¡erence between the three immunolipo-
Fig. 6. E¡ect of attachment of PEG chains to the surface of
immunoliposomes with antibody coupled either directly to the
liposomal surface or to the distal end of the PEG chains on the
metabolic fate of liposome incorporated [3H]FUdR-dP. (A) As-
sociation of 3H-labeled drug with CC531 cells after incubating
cells with [3H]FUdR-dP incorporated in CC52-MPB liposomes
(159 Wg CC52/Wmol lipid) (a), CC52-MPB-PEG liposomes (32
Wg CC52/Wmol lipid) (O) or CC52-Hz-PEG liposomes (13 Wg
CC52/Wmol lipid), or by adding free [3H]FUdR (E). Cells were
incubated with 50 nmol immunoliposomes containing FUdR-dP
or the equivalent amount of free drug (2 nmol) for 3 h, fol-
lowed by a drug-free incubation time of 3 or 6 h, both in the
absence of 10% FCS (n = 6). (B) Hydrolysis of [3H]FUdR-dP
from CC52-MPB liposomes (a), CC52-MPB-PEG liposomes
(O) or CC52-Hz-PEG liposomes (R). 3H-Label in the medium
was determined after a 3-h incubation with liposomes followed
by liposome-free incubation period (n = 6). (C) Rate of hydroly-
sis of cell-bound immunoliposomal [3H]FUdR-dP from CC52-
MPB liposomes (a), CC52-MPB-PEG liposomes (O) or CC52-
Hz-PEG liposomes (R) in time after a 3-h incubation period as
revealed by the appearance of 3H-label in the medium, plotted
as a percentage of the total label retrieved (n = 6).
C
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somal formulations in the way they deliver the drug
to the tumor cells.
4. Discussion
In this report we address the mechanism by which
an immunoliposomal drug delivery system for the
anticancer drug FUdR is able to deliver FUdR intra-
cellularly into colon cancer cells.
The interaction of CC52 immunoliposomes with
CC531 cells resulted in degradation of less than
20% of the liposomes associating with the cells within
48 h, as shown by the hydrolysis of liposomal cho-
lesterol ester (Fig. 2A,B). Morphological studies with
colloidal gold-containing immunoliposomes revealed
that, in a vast majority of the tumor cells, the im-
munoliposomes remain bound at the cell surface
without internalization, although occasionally cells
were observed with liposomal gold grains inside.
Thus, the internalization of limited amounts of im-
munoliposomes by the CC531 cells, as revealed by
the limited hydrolysis of cholesterol ester, is most
likely due to heterogeneity in the cell population.
The low level of internalization of immunolipo-
somes may explain the fraction of immunoliposomes
that cannot be removed by trypsin treatment (Fig.
1B,C). An alternative or complementary explanation
for this e¡ect is an increase in the strength or multi-
valency of the binding of the immunoliposomes to
CC531 cells in time. Evidence pointing in this direc-
tion was obtained, indirectly, from incubations per-
formed at 4‡C. Immunoliposomes bound to CC531
cells at 4‡C were removed by trypsin treatment more
e¡ectively than immunoliposomes bound at 37‡C.
Such di¡erence in interaction between 4‡C and
37‡C may ¢nd its origin in the rigidifying e¡ect of
the low temperature on either the plasma membrane
or the liposomal bilayer. This may restrict intrabi-
layer mobility of phospholipid-anchored antibodies
and likely also of cell-surface antigens, resulting in
fewer antibody molecules interacting with antigens
and consequently in increased amounts of liposomes
removed by trypsin at 4‡C. Decreased intrabilayer
movement of liposome-associated molecules in sol-
id-type liposomes was proposed before to result in
a decrease of the valency of interaction of liposomes
with cells [28]. In view of the generally accepted non-
exchangeability of cholesterol esters and ethers [29],
we consider it unlikely that exchange of these labels
between immunoliposomes and plasma membrane
signi¢cantly contributes to the phenomena described.
Although internalization of immunoliposomes by
tumor cells has been reported, quantities are mostly
low [8,11,30]. Other reports in literature describe a
complete lack of uptake of immunoliposomes [9,12].
The type of antigen that is targeted seems to play a
minor role in determining whether or not the lipo-
somes are taken up. For instance, immunoliposomes
targeted to the HER-2 antigen were reported to be
e⁄ciently internalized by human breast cancer cells
[9,30], less e⁄ciently by MKN-7 human gastric or
SKOV-3 ovarian carcinoma cells [30] and not at all
by N-87 human gastric carcinoma cells [9]. Mecha-
nisms triggering such uptake of immunoliposomes
are still not fully understood.
In contrast to the liposomal cholesterol ester, the
immunoliposome-incorporated lipophilic prodrug
FUdR-dP is readily and almost completely hydro-
lyzed by the tumor cells, showing that uptake of
the prodrug proceeds independent of internalization
of the immunoliposomes as such. Within 24 h virtu-
ally all immunoliposomal FUdR-dP that was cell-as-
sociated after a 3-h incubation period, is hydrolyzed
by the tumor cells (Fig. 4 and Table 2). FUdR from
hydrolyzed FUdR-dP appears predominantly in the
medium (80^90%), while 10^20% remains intracellu-
lar. However, when comparing the extra- and intra-
cellular FUdR-concentrations, it appears that the in-
tracellular concentration reaches 700- to 3000-fold
higher levels than that in the medium. It remains
to be seen how much of the intracellular FUdR is
present as free drug, because FUdR or metabolites
can be incorporated into DNA and RNA [31] or
associate with thymidylate synthase [32]. In a pre-
vious study we have shown that the intracellular
FUdR is e¡ective in inhibiting CC531 cell growth
[13].
The high intracellular concentration of hydrolyzed
prodrug strongly suggests that the hydrolysis process
occurs rapidly and is situated intracellularly. This is
con¢rmed by the strong inhibition of hydrolysis of
immunoliposomal FUdR-dP by a host of inhibitors
of endocytosis or intralysosomal degradation. Col-
chicine had no signi¢cant inhibitory e¡ect on the
hydrolysis of FUdR-dP, indicating that microtubules
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appear to have no function in this process. It has
been shown before that colchicine and other micro-
tubule-depolymerizing drugs have only minor e¡ects
on the uptake of immunoliposomes by Kup¡er cells
[33] and on the degradation of internalized proteins
in a human carcinoma HEp-2 [34].
Taken together, these results lead us to postulate a
selective transfer mechanism for immunoliposomal
FUdR-dP. During the antibody^antigen-mediated
interaction of CC52 liposomes and CC531 cells,
FUdR-dP presumably is transferred from the liposo-
mal bilayer to the plasma membrane of tumor cells,
internalized by constitutive endocytic or pinocytic
processes and hydrolyzed intralysosomally. Subse-
quently, the hydrolyzed prodrug di¡uses into the cy-
toplasm from where it is either released into the ex-
tracellular compartment (medium) or utilized
intracellularly for incorporation into nucleic acids.
In both cases the drug can exert its cytotoxic e¡ect:
when remaining intracellular, it will have detrimental
e¡ects on DNA and RNA [31] and will inhibit DNA-
synthesis by inhibiting thymidylate synthase [32].
Drug that is released from the tumor cell, in which
it is hydrolyzed, can di¡use into surrounding tumor
cells. This will constitute a favorable condition espe-
cially in case tumor cells are present that do not
express the antigen on their surface, resulting in a
so-called bystander e¡ect. Hydrolyzed FUdR-dP re-
leased by Kup¡er cells was shown before to display
antitumor activity against C26 murine colon carcino-
ma [19].
The lipophilic prodrug FUdR-dP was proposed
earlier to transfer from the bilayer of immunolipo-
somes to the plasma membrane of lung-endothelium
cells as a result of the antibody^antigen-mediated
interaction of the liposomes with the endothelial cells
[15]. In a comparable way phosphatidylcholine trans-
fer from liposomes containing the ganglioside GM1
or lactosylceramide to hepatocytes was observed [35]
and proposed to be mediated by an enhanced inter-
action between the liposomes and the hepatocytes
[36]. Also, cellular uptake of a liposome-associated
lipophilic derivative of methotrexate has been re-
ported suggesting a mechanism of liposomal drug
uptake without the need of internalization of the
entire liposome [37,38].
Neither the rate of transfer of FUdR-dP nor the
hydrolysis of cell-associated FUdR-dP is hampered
by the presence of 4 mol% PEG2000 on the surface of
CC52-MPB liposomes or by the coupling of anti-
body to the distal end of the PEG chains in the
case of CC52-Hz-PEG liposomes (Fig. 6C). The low-
er levels of cell-associated FUdR-dP (Fig. 6A) and
the concomitantly lower amounts of hydrolyzed pro-
drug in the medium (Fig. 6B) after incubations with
PEG immunoliposomes can be explained by a lower
amount of PEG immunoliposomes binding to the
tumor cells. This, in turn, is most likely caused by
the lower antibody density on the surface of PEG
liposomes as mentioned in the method section. Still,
PEG immunoliposomes much more e⁄ciently deliv-
ered FUdR-dP to the tumor cells than liposomes
without antibody (Table 4) or free FUdR (Fig.
6A). This is a relevant consideration in view of the
preferred use in vivo of long-circulating PEG lipo-
somes. Combined with the una¡ected rate of hydrol-
ysis of FUdR-dP in PEG immunoliposomes com-
pared to non-PEG immunoliposomes, it illustrates
that much higher intracellular levels of FUdR can
be attained by PEG immunoliposomes than by lip-
osomes without antibody or by free FUdR.
At present, we can only speculate on the mecha-
nism of this transfer. Direct transfer from liposome
bilayer to plasma membrane seems unlikely, since the
presence of both the antigen^antibody bridge and the
7-nm PEG chains are expected to maintain a sub-
stantial distance between the two bilayers. Moreover,
when the antibody is coupled at the distal end of the
PEG chain, resulting in an even larger distance be-
tween the bilayers upon antibody^antigen interac-
tion, we see no di¡erence in prodrug transfer. Trans-
fer through the aqueous phase would therefore seem
to be more likely. The rate-limiting step in that case
would be the release of the prodrug from the liposo-
mal bilayer. The in£uence of serum factors on this
process can be abolished as we showed previously; in
non-immunoliposomes the prodrug remains tightly
associated with the liposomes, even during prolonged
incubation at 37‡C in plasma [39]. These observa-
tions are in line with the lack of in£uence of serum
on the results presented in Table 2 and Fig. 4 as
emphasized in Section 3.4. Presumably, the anti-
body^antigen interaction on the cell surface results
in conditions less favorable for the prodrug molecule
to remain accommodated in the liposomal mem-
brane.
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The drug delivery mechanism described in this pa-
per combines e⁄cient delivery with the lack of need
for internalization of the liposomes and provides an
e⁄cient system for the delivery of FUdR to colon
cancer cells. It may also serve as a model system
for the development of new (targetable) liposomal
drug delivery systems for non-phagocytic cells by
exploiting the liposomal bilayer for incorporation
of lipophilic drugs or prodrugs.
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